{
    "clinical_study": {
        "@rank": "65534", 
        "arm_group": [
            {
                "arm_group_label": "Chloride-rich IV fluid", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice."
            }, 
            {
                "arm_group_label": "Chloride-poor IV fluid", 
                "arm_group_type": "Active Comparator", 
                "description": "A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice."
            }
        ], 
        "brief_summary": {
            "textblock": "This primary aim of this study is to test the impact of a strategy of perioperative\n      chloride-restriction through intravenous (IV) fluid therapy on the incidence of acute kidney\n      injury after cardiac surgery.\n\n      A prospective, open-label, single-centre 4-period sequential study of varying strategies of\n      perioperative IV fluid composition will test the hypothesis that a perioperative protocol\n      for the administration of chloride-poor intravenous fluids compared to chloride-rich\n      intravenous fluids will reduce the incidence of AKI after adult cardiothoracic surgery."
        }, 
        "brief_title": "Does the Chloride Content of Intravenous Fluid Alter the Risk of Acute Kidney Injury After Cardiac Surgery?", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients Undergoing Cardiothoracic Surgery", 
        "condition_browse": {
            "mesh_term": [
                "Acute Kidney Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "After an initial run-in period of approximately 1 month (using a chloride-rich fluid\n      strategy), the first study period of 5 months will commence, also comprising a chloride-rich\n      perioperative IV fluid therapy strategy (0.9% saline or 4% albumin).  This will include\n      intraoperative fluid and postoperative fluid for the duration of stay in the intensive care\n      unit.  This will then be followed by a 1-month transition period before a second period of 5\n      months will commence where perioperative intravenous fluid therapy will consist of\n      chloride-poor fluids (Lactated Ringer's solution or concentrated 20% albumin).  A subsequent\n      1-month transition period will then be followed by a third period of 5 months characterized\n      by perioperative IV fluid therapy with an alternative combination of chloride-poor solutions\n      (PlasmaLyte\u00ae 148 or concentrated 20% albumin).  A final 1-month transition period will be\n      followed by a fourth and final period of 5 months characterized by a return to perioperative\n      IV fluid therapy with chloride-rich fluids (0.9% saline or 4% albumin).  A final 1-month\n      run-off period using a chloride-rich perioperative fluid strategy will follow prior to study\n      completion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All adult patients undergoing surgery by Division of cardiothoracic surgery\n\n        Exclusion Criteria:\n\n        Nil"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020538", 
            "org_study_id": "382/13"
        }, 
        "intervention": {
            "arm_group_label": "Chloride-poor IV fluid", 
            "description": "The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.", 
            "intervention_name": "Low-chloride perioperative intravenous fluid strategy", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Thoracic surgery", 
            "cardiac surgery", 
            "acute kidney injury", 
            "hyperchloremia", 
            "intravenous fluid"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "d.mcilroy@alfred.org.au", 
                "last_name": "David R McIlroy, MBBS, MClinEpi, FANZCA", 
                "phone": "+61390762000", 
                "phone_ext": "63176"
            }, 
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Alfred Hospital"
            }, 
            "investigator": {
                "last_name": "David R McIlroy, MBBS, MClinEpi, FANZCA", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Does Varying the Chloride Content of Intravenous Fluid Alter the Risk of Acute Kidney Injury After Cardiac Surgery?", 
        "other_outcome": {
            "description": "A dose response effect between mean postoperative serum chloride concentration and adverse outcomes, including delta serum creatinine and AKI, will be assessed for.", 
            "measure": "Mean postoperative serum chloride concentration while in ICU", 
            "safety_issue": "No", 
            "time_frame": "First 5 days and through ICU admission"
        }, 
        "overall_contact": {
            "email": "d.mcilroy@alfred.org.au", 
            "last_name": "David R McIlroy, MBBS, MClinEpi, FANZCA", 
            "phone": "+61390762000", 
            "phone_ext": "63176"
        }, 
        "overall_official": {
            "affiliation": "The Alfred", 
            "last_name": "David R McIlroy, MBBS, MClinEpi, FANZCA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Peak delta serum creatinine and Class 2 or greater AKI, defined by KDIGO criteria, while in ICU. (Co-primary outcomes)", 
            "safety_issue": "No", 
            "time_frame": "5 days postoperatively and duration of ICU admission postoperatively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020538"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary outcomes will include individual stages of AKI and their duration (defined by KDIGO criteria), renal replacement therapy and duration, renal function at discharge, 30 and 90 days postoperatively, hospital mortality, length of stay in the ICU and hospital, time to extubation and transfusion requirements.", 
            "measure": "Individual stages of AKI, RRT, renal function at discharge, 30 days and 90 days postoperatively, hospital mortality, length of stay, time to extubation and transfusion requirements", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "source": "Bayside Health", 
        "sponsors": {
            "collaborator": {
                "agency": "Australian and New Zealand College of Anaesthetists", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Bayside Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}